CN113874014A - 用于治疗痛风或高尿酸血症的化合物 - Google Patents

用于治疗痛风或高尿酸血症的化合物 Download PDF

Info

Publication number
CN113874014A
CN113874014A CN202080035809.1A CN202080035809A CN113874014A CN 113874014 A CN113874014 A CN 113874014A CN 202080035809 A CN202080035809 A CN 202080035809A CN 113874014 A CN113874014 A CN 113874014A
Authority
CN
China
Prior art keywords
compound
effective amount
therapeutically effective
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080035809.1A
Other languages
English (en)
Chinese (zh)
Inventor
颜顺启
叶立天
颜戎子
沈赞聪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Ruianbo Pharmaceutical Technology Co ltd
Original Assignee
Arthrosi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthrosi Therapeutics Inc filed Critical Arthrosi Therapeutics Inc
Publication of CN113874014A publication Critical patent/CN113874014A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
CN202080035809.1A 2019-05-14 2020-05-13 用于治疗痛风或高尿酸血症的化合物 Pending CN113874014A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847519P 2019-05-14 2019-05-14
US62/847,519 2019-05-14
PCT/US2020/032725 WO2020232156A1 (en) 2019-05-14 2020-05-13 Compound for treating gout or hyperuricemia

Publications (1)

Publication Number Publication Date
CN113874014A true CN113874014A (zh) 2021-12-31

Family

ID=73288915

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080035809.1A Pending CN113874014A (zh) 2019-05-14 2020-05-13 用于治疗痛风或高尿酸血症的化合物

Country Status (14)

Country Link
US (2) US20220242841A1 (enExample)
EP (1) EP3968989A4 (enExample)
JP (1) JP7656548B2 (enExample)
KR (1) KR102971948B1 (enExample)
CN (1) CN113874014A (enExample)
AU (2) AU2020274165A1 (enExample)
BR (1) BR112021022843A2 (enExample)
CA (1) CA3140412A1 (enExample)
IL (1) IL288034B2 (enExample)
MA (1) MA55973A (enExample)
MX (1) MX2021013980A (enExample)
SG (1) SG11202112562XA (enExample)
TW (1) TW202108561A (enExample)
WO (1) WO2020232156A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164439A (zh) 2018-12-06 2021-07-23 安索治疗公司 用于治疗或预防痛风或高尿酸血症的方法
JP2022511800A (ja) 2018-12-06 2022-02-01 アースローシ セラピューティクス，インク． 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
KR20230024354A (ko) * 2020-06-10 2023-02-20 아쓰로시 테라퓨틱스, 인크. 만성 신장 질환을 치료 또는 예방하는 방법
WO2023058975A1 (ko) * 2021-10-07 2023-04-13 (주)이노보테라퓨틱스 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물
WO2023098872A1 (en) * 2021-12-02 2023-06-08 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
WO2023125667A1 (en) * 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia
US20250242050A1 (en) 2024-01-31 2025-07-31 The Industry & Academic Cooperation In Chungnam National University (Iac) Composition for treating gout containing cyclodextrin-conjugated polymer nano-drug and method for treating gout

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017368A1 (en) * 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962362B2 (en) * 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
WO2019195118A1 (en) * 2018-04-03 2019-10-10 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
JP2022511800A (ja) * 2018-12-06 2022-02-01 アースローシ セラピューティクス，インク． 痛風または高尿酸血症を処置または予防するための化合物の結晶形態

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017368A1 (en) * 2016-07-18 2018-01-25 Arthrosi Therapeutics, Llc Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Also Published As

Publication number Publication date
IL288034A (en) 2022-01-01
AU2026202224A1 (en) 2026-04-09
CA3140412A1 (en) 2020-11-19
JP2022533958A (ja) 2022-07-27
BR112021022843A2 (pt) 2022-03-03
EP3968989A1 (en) 2022-03-23
SG11202112562XA (en) 2021-12-30
IL288034B1 (en) 2026-04-01
AU2020274165A1 (en) 2022-01-06
MX2021013980A (es) 2022-04-01
US20260200884A1 (en) 2026-07-16
KR20220016105A (ko) 2022-02-08
IL288034B2 (en) 2026-08-01
TW202108561A (zh) 2021-03-01
US20220242841A1 (en) 2022-08-04
JP7656548B2 (ja) 2025-04-03
KR102971948B1 (ko) 2026-06-01
WO2020232156A1 (en) 2020-11-19
MA55973A (fr) 2022-03-23
EP3968989A4 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
US20250059150A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
JP7656548B2 (ja) 痛風または高尿酸血症を処置するための化合物
JP7528080B2 (ja) 痛風または高尿酸血症を処置または予防するための方法
WO2023098872A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
HK40060723A (en) Compound for treating gout or hyperuricemia
CN119836422A (zh) S1p受体调节剂的结晶形式
HK40056575A (en) Methods for treating or preventing gout or hyperuricemia
EA049585B1 (ru) Соединение для лечения подагры или гиперурикемии
HK40056574A (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
HK40056574B (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right

Effective date of registration: 20211230

Address after: Room 1501, No. 27, Huanyu 1st Road, Guangzhou International Biological Island, Huangpu District, Guangzhou, Guangdong

Applicant after: Guangzhou ruianbo Pharmaceutical Technology Co.,Ltd.

Address before: California, USA

Applicant before: ARTHROSI THERAPEUTICS, Inc.

TA01 Transfer of patent application right
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060723

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20211231

RJ01 Rejection of invention patent application after publication